{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=51", "query": { "condition": "Multiple Cancers", "page": 51 }, "page_size": 10 }, "pagination": { "page": 51, "page_size": 10, "total_count": 4777, "total_pages": 478, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=52&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=50&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T20:43:16.879Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03652064", "title": "A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 395, "start_date": "2018-11-06", "completion_date": "2026-04-21", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-11-01T20:43:16.879Z", "location_count": 19, "location_summary": "Cerritos, California • Jacksonville, Florida • Fort Wayne, Indiana + 15 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03652064" }, { "nct_id": "NCT01541332", "title": "Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin (PLD)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2012-02", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2016-03-10", "last_synced_at": "2026-11-01T20:43:16.879Z", "location_count": 8, "location_summary": "Burbank, California • Encinitas, California • Fresno, California + 5 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01541332" }, { "nct_id": "NCT01758328", "title": "Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "anti-thymocyte globulin (ATG)", "type": "BIOLOGICAL" }, { "name": "a T cell depleted stem cell transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "21 Years to 72 Years" }, "enrollment_count": 29, "start_date": "2012-12", "completion_date": "2025-03-17", "has_results": false, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-11-01T20:43:16.879Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01758328" }, { "nct_id": "NCT06410300", "title": "Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Curative Radiotherapy", "type": "RADIATION" }, { "name": "Immunotherapy", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Bo Lu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2024-04-19", "completion_date": "2030-04-19", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-11-01T20:43:16.879Z", "location_count": 3, "location_summary": "Columbia, Missouri • New Brunswick, New Jersey • Rochester, New York", "locations": [ { "city": "Columbia", "state": "Missouri" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06410300" }, { "nct_id": "NCT00454090", "title": "AZD8330 First Time in Man in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "AZD8330", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2007-03", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2011-08-24", "last_synced_at": "2026-11-01T20:43:16.879Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00454090" }, { "nct_id": "NCT00003490", "title": "Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 30, "start_date": "1998-10", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-11-01T20:43:16.879Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003490" }, { "nct_id": "NCT06953960", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Surzetoclax", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Etentamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2025-07-23", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-01T20:43:16.879Z", "location_count": 12, "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06953960" }, { "nct_id": "NCT03190824", "title": "Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage Iv" ], "interventions": [ { "name": "OBP-301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syneos Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-12-22", "completion_date": "2021-10-31", "has_results": false, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-11-01T20:43:16.879Z", "location_count": 1, "location_summary": "Morristown, New Jersey", "locations": [ { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03190824" }, { "nct_id": "NCT01773408", "title": "A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelogenous Leukemia, Acute" ], "interventions": [ { "name": "RO5503781 MBP", "type": "DRUG" }, { "name": "RO5503781 SDP", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2013-02", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2017-01-25", "last_synced_at": "2026-11-01T20:43:16.879Z", "location_count": 4, "location_summary": "Los Angeles, California • Valhalla, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Valhalla", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01773408" }, { "nct_id": "NCT01363817", "title": "Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute T-cell", "Precursor T-Cell Lymphoblastic Lymphoma" ], "interventions": [ { "name": "BMS-906024", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2011-09-28", "completion_date": "2018-02-07", "has_results": false, "last_update_posted_date": "2019-07-30", "last_synced_at": "2026-11-01T20:43:16.879Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01363817" } ] }